150 related articles for article (PubMed ID: 28138305)
1. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
2. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study.
Mall AS; Chirwa N; Govender D; Lotz Z; Tyler M; Rodrigues J; Kahn D; Goldberg P
Pathol Int; 2007 Aug; 57(8):537-47. PubMed ID: 17610480
[TBL] [Abstract][Full Text] [Related]
3. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
4. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
5. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
[TBL] [Abstract][Full Text] [Related]
6. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
8. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an
Pillai K; Akhter J; Morris DL
Pleura Peritoneum; 2017 Jun; 2(2):111-117. PubMed ID: 30911639
[TBL] [Abstract][Full Text] [Related]
10. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
11. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
Amini A; Masoumi-Moghaddam S; Ehteda A; Morris DL
Orphanet J Rare Dis; 2014 May; 9():71. PubMed ID: 24886459
[TBL] [Abstract][Full Text] [Related]
12. Acidic glycosaminoglycans of abdominal mucin in a case of pseudomyxoma peritonei caused by appendiceal cancer.
Miyashita T; Murata K; Hoshino E; Nishiya H; Ono Y; Akaoka I; Kunii O
Dig Dis Sci; 1999 Nov; 44(11):2231-4. PubMed ID: 10573367
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters.
Akhter J; Pillai K; Chua TC; Alzarin N; Morris DL
Am J Cancer Res; 2014; 4(5):495-507. PubMed ID: 25232491
[TBL] [Abstract][Full Text] [Related]
14. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
[TBL] [Abstract][Full Text] [Related]
15. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
[TBL] [Abstract][Full Text] [Related]
16. Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions.
Davies JR; Svitacheva N; Lannefors L; Kornfält R; Carlstedt I
Biochem J; 1999 Dec; 344 Pt 2(Pt 2):321-30. PubMed ID: 10567212
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and biochemical characterization of mucin in pseudomyxoma peritonei: a case study.
Mall AS; Lotz Z; Tyler M; Goldberg P; Rodrigues J; Kahn D; Chirwa N; Govender D
Case Rep Gastroenterol; 2011 Jan; 5(1):5-16. PubMed ID: 22347149
[TBL] [Abstract][Full Text] [Related]
18. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
19. Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors.
Dilly AK; Lee YJ; Zeh HJ; Guo ZS; Bartlett DL; Choudry HA
Transl Res; 2016 Mar; 169():19-30.e1. PubMed ID: 26589109
[TBL] [Abstract][Full Text] [Related]
20. Ovarian mucinous tumor arising in mature cystic teratoma associated with pseudomyxoma peritonei: a case with possible respiratory epithelial differentiation.
Stewart CJ; Junckerstorff R; Tsukamoto T
Int J Gynecol Pathol; 2008 Jan; 27(1):41-3. PubMed ID: 18156973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
